Isoprostanes: Potential markers of oxidant stress in atherothrombotic disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 11, 1997, Pages 2309-2315

  Patrono, Carlo ^a   FitzGerald, Garret A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cigarette smoking; F2 isoprostanes; Hypercholesterolemia; Ischemia reperfusion; Lipid peroxidation

Indexed keywords

11 OXOTHROMBOXANE B2; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; ARACHIDONIC ACID; CHOLESTEROL; DEXAMETHASONE; DNA; FATTY ACID; FREE RADICAL; GLYCOSYLATED PROTEIN; HYDROPEROXIDE; LEUKOTRIENE; LIPID; LIPOPROTEIN; PHOSPHOLIPID; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROSTANOID RECEPTOR; REACTIVE OXYGEN METABOLITE; SCAVENGER; STREPTOKINASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THROMBOXANE A2;

ACUTE HEART INFARCTION; ARACHIDONIC ACID METABOLISM; ATHEROGENESIS; ATHEROSCLEROSIS; CIGARETTE SMOKING; CLINICAL TRIAL; DIABETES MELLITUS; GAS CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOASSAY; ISCHEMIA; LIPID PEROXIDATION; MASS SPECTROMETRY; OXIDATIVE STRESS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; THROMBOCYTE;

EID: 0031471077     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.11.2309     Document Type: Review

References (17)

1. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM. The yin and yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol. 1996;16:831-842.
2. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
3. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-1792.
4. O'Connor DE, Mihelic ED, Coleman MC. Stereochemical course of the auto-oxidative cyclization of lipid hydroperoxides to prostaglandin-like bicyclo endoperoxides. J Am Chem Soc. 1984;106: 3577-3584.
5. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 1990;87:9383-9387.
6. Lynch SM, Morrow JD, Roberts LJ II, Frei B. Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. J Clin Invest. 1994;93:998-1004.
7. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271: 33157-33160.
8. 2-isoprostane) metabolites in human urine and plasma. J Biol Chem. 1993;268:4161-4169.
9. 2α excretion in man. J Pharmacol Exp Ther. 1995;275:94-100.
10. 2αby human monocytes: discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem. 1996;271:8919-8924.
11. 2 isoprostanes in human atherosclerotic lesions. J Clin Invest. 1997; 100:2028-2034.
12. 2α. J Biol Chem. 1995;270:9800-9808.
13. 2-isoprostane formation. Br J Pharmacol. 1996;118:1285-1293.
14. Panara MR, Greco A, Santini G, Sciulli G, Rotondo MT, Padovano R, Di Giamberardino M, Cipollone F, Cuccurullo F, Patrono C, Patrignani P. Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphon amido-6-(2,4-difluorothiophenyl)-1-indanone (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. Br J Pharmacol. 1995; 116:2429-2434.
15. 2 receptors. J Clin Invest. 1992;90:136-141.
16. 2-isoprostane receptors on rat vascular smooth muscle cells. Am J Physiol. 1993;264: C1619-1624.
17. 2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins. 1992;44:155-163.